Psychiatry
We are committed to the research and discovery of novel pathways and therapies to address some of the world's most serious psychiatric conditions. Our goal is to develop therapies that transform the lives of people living with these conditions.
A Decade of Innovation
Over the past 10 years, we have made it our mission to serve the psychiatric community of more than 14 million people living with bipolar disorder and schizophrenia in the United States. We continue to investigate some of the world's most serious mental disorders to help improve the lives of patients with these conditions.
Bipolar Depression*
29M
12.6M
Schizophrenia*
20M
1M
Our Medicines
LATUDA is a prescription medicine used to treat adults and adolescents (13 to 17 years) with schizophrenia. Alone to treat adults, children and teens (10 to 17 years) with depressive episodes that happen with bipolar I disorder (bipolar depression). With the medicine lithium or valproate to treat adults with depressive episodes that happen with bipolar I disorder (bipolar depression).
Please read the full Prescribing Information, including Boxed Warning for Latuda.
For HCP information, please visit: Visit Latuda HCP site
For patient information, please visit: Visit Latuda patient site
What is
Sunovion Answers?
We believe in putting people first, which is why we created Sunovion Answers. Our caring and skilled team is available to provide knowledge and resources to help patients, caregivers, family members, or providers. We’re committed to finding solutions and connecting people to the information they need.
Specialists are available anytime between 8AM and 8PM (ET): 1-855-552-8832
Our Psychiatry Pipeline
We are committed to the investigation and discovery of novel therapies to help people living with serious mental health conditions. From identifying new pathways to treat schizophrenia to advancing new candidates for bipolar depression, our work never stops.
Therapeutic Area
Candidate
Indication/Target
Phase
Psychiatry
Ulotaront (SEP-363856)
Schizophrenia
Phase 3 75% complete
Psychiatry
Ulotaront (SEP-363856)
Adjunctive major depressive disorder
Phase 3 75% complete
Psychiatry
Ulotaront (SEP-363856)
Generalized anxiety disorder
Phase 3 75% complete
Psychiatry
SEP-4199
Bipolar depression
Phase 3 75% complete
Psychiatry
SEP-378614
Treatment-resistant depression
Phase 1 25% complete
Psychiatry
DSP-0038
Alzheimer's disease psychosis
Phase 1 25% complete
Psychiatry
DSP-3456
Treatment-resistant depression
Phase 1 25% complete
Psychiatry
DSP-2342
To be determined
Phase 1 25% complete
Therapeutic Area
Indication/Target
Candidate
Schizophrenia
Ulotaront
(SEP-363856)
Phase 3 75% complete
Adjunctive major depressive disorder
SEP-363856
Phase 3 75% complete
Generalized anxiety disorder
SEP-363856
Phase 3 75% complete
Bipolar depression
SEP-4199
Phase 3 75% complete
Treatment-resistant depression
SEP-378614
Phase 1 25% complete
Alzheimer's disease psychosis
DSP-0038
Phase 1 25% complete
Treatment-resistant depression
DSP-3456
Phase 1 25% complete
To be determined
DSP-2342
Phase 1 25% complete
Featured Publications
I’m passionate about advancing our team’s work to deliver the next generation of innovative treatment options for patients living with serious mental health conditions.
